Vaccines and biologics, stable at any temperature.
AmberVax preserves living biology in a glass-like amber matrix — eliminating the cold chain, extending shelf life beyond a decade, and unlocking global access to modern medicine.
Three sciences. One stable formulation.
AmberVax combines proprietary vitrification, dehydration kinetics, and excipient design to lock biological cargo into an amorphous amber matrix — preserving structure and activity without refrigeration.
Vitrification science
Proprietary excipient systems from Cyternity transform liquid drug substance into a stable, glass-like amorphous solid — preserving conformation at the molecular level.
Ambient stability
Vitrilife and Vitrisera processes demonstrate years of shelf life at 25 °C and beyond, validated across vaccines, antibodies, viral vectors and cell-derived products.
Drop-in manufacturing
Compatible with existing fill-finish lines, vials and prefilled formats — no new equipment required for scale-up.
From mRNA to monoclonals, stabilized.
The AmberVax platform is modality-agnostic. We've stabilized lipid nanoparticles, viral vectors, protein subunit vaccines, mAbs and live attenuated organisms — each formulated for ambient storage and rapid reconstitution.
- mRNA / LNP vaccines
- Viral vector vaccines (AAV, adenovirus)
- Monoclonal antibodies
- Live attenuated & subunit vaccines
Bring your molecule. We'll make it shelf-stable.
We work with pharma and biotech partners on feasibility studies, joint development programs and licensed manufacturing.
Start a conversation